#Niger : des organisations de la société civile ont organisé un sit-in devant la délégation de l' #UE à #Niamey pour protester contre la résolution du Parlement européen demandant la libération de l'ex-président Mohamed Bazoum. Des autorités et membres du #CNSP étaient présents.

CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline CNS Pharmaceuticals (NASDAQ:CNSP) announced a strategic pivot on March 11, 2026 toward building a high-value pipeline focused on neurology and oncology, led by a newly formed executive team. The company completed a rigorous, data-driven review and plans to pursue acquisitions or in-licensing of preclinical and clinical-stage assets.CNSP said it will explore out-licensing of legacy assets berubicin and TPI 287 to concentrate resources on differentiated programs with defined value inflection points and unmet medical need.

#CNSP CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline

www.stocktitan.net/news/CNSP/cns-pharmaceut...

CNS Pharmaceuticals Issues Letter to Shareholders CNS Pharmaceuticals (NASDAQ:CNSP) issued a letter from newly appointed President and CEO Rami Levin outlining a strategic evaluation of the company on January 27, 2026. The CEO said the review covers the pipeline, development priorities, operations and capital allocation, with three guiding principles: Patients First, Pipeline Enrichment and Optimization, and Disciplined Value Creation. The company identified TPI 287 as its lead asset and core value driver and plans to refine clinical and regulatory strategies, prioritize indications, align with regulators and raise capital toward data and milestone achievements.

#CNSP CNS Pharmaceuticals Issues Letter to Shareholders

www.stocktitan.net/news/CNSP/cns-pharmaceut...

#CNSP CNS Pharmaceuticals Announces CEO Transition

www.stocktitan.net/news/CNSP/cns-pharmaceut...

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update Cash expected to fund operations into the second half of 2026Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the blood-brain barrier, potentially enhancing efficacy for patientsLead program, TPI 287, progressing

#CNSP CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CNSP/cns-pharmaceut...

CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that

#CNSP CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting

www.stocktitan.net/news/CNSP/cns-pharmaceut...

Niger : Le général Tiani est attendu à Dosso les 8 et 9 novembre 2025, selon un communiqué du Sultanat de Dosso.
Le programme prévoit un accueil sur la voie Niamey–Dosso–Gaya samedi et un meeting dimanche à l’arène de lutte Salma Dan Rani.
#Niger #Dosso #Tiani #CNSP

Au Niger, le Général Tiani précise les missions du Premier ministre. - NigerFocus Un peu plus de deux ans après la nomination du Premier ministre, le président de la république définit ses missions.   Nigerfocus le 6 novembre 2025 : Dans une ordonnance signée le 28 octobre dernier ...

Le #président nigérien renforce les pouvoirs du #Premier_ministre un peu plus de deux après la nomination de Ali Mahamane Lamine Zeine. #Niger #CNSP
nigerfocus.com/2025/11/06/a...

🇳🇪 #Niger, Le peuple crève, la junte légalise le pillage : comité, ordonnance, point de presse… tout y est.
L’escroquerie est désormais institutionnelle.

La “sauvegarde de la patrie” ? Non. Sauvegarde de leurs poches.

#FSSP #CNSP #VolAvecOrdonnance #SouverainetéDeLaMendicité #BraquageOfficiel

🔥 CNSP 2025 au Mans : revivez les expositions ! Impossible d'y être ? On vous emmène en vidéo (20 min) dans les halls d'expo avec Guy Condamine : Hall D et Rotonde

youtu.be/AeiXmynDPQE

#Pompiers #SDIS #SécuritéCivile #CNSP #LeMans #SapeursPompiers #Innovation

🇳🇪 Douanes du Niger : recrutement express, remplacements surprises !
Chaque mois on change… parfois même 2 fois !
Le pouvoir joue au « Musical Chair » à la douane ; le peuple, lui, joue à « Attends‑et‑voir »
Résultat : une institution fragile, un service en panne.

#Niger #CNSP #Douanes #Incompétence

✈️ Air Tiani Internationales : la nouvelle blague de la junte.

Après l’échec total sur la sécurité, le coût de la vie et la paix, voilà une autre promesse : une "compagnie aérienne"

➡️ Quand on ne peut même pas sécuriser les routes… on rêve d’avions ?

#Niger #CNSP #PromessesVides #TianiAirlines

1/3 Au #Niger, un peu plus de 2 ans après le putsch contre Mohamed #Bazoum, le CCLD BUKATA dresse un « bilan mitigé » du #CNSP, au pouvoir depuis juillet 2023. ⤵️

Brain Cancer Breakthrough: CNS Pharma's TPI 287 Shows 52% Response Rate in Phase 1 GBM Trial CNS Pharmaceuticals reports $12.1M cash position funding ops into H2 2026. TPI 287 achieved 12/23 responses in Phase 1 GBM trial. Plans Phase 2 study in H1 2026 with FDA orphan drug status.

#CNSP CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CNSP/cns-pharmaceut...

Au Niger, l’armée rend hommage aux blessés de guerre.  - NigerFocus Après 65 ans dont une dizaine de combats avec des terroristes, l’armée rend hommage aux blessés de guerre. Ils ont eu les honneurs de la république ce 1er août 2025, date anniversaire de la création d...

#Niger l' #armée marque son anniversaire avec l'hommage rendu aux blessés de #guerre. #Tiani #CNSP nigerfocus.com/2025/08/02/a...

Niger : Le 26 juillet, jour anniversaire de la prise de pouvoir par le CNSP, est déclaré férié, chômé et payé sur toute l’étendue du territoire national, annonce le ministère de la Fonction publique. #Niger #CNSP #FêteNationale

News; ( NASDAQ: #CNSP ) InvestorNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Virtual Investor Summer Spotlight Conference

Breaking News: ( NASDAQ: #CNSP ) Unexpected Finding Potentially Opens the Door to Universal Vaccines Against Cancer

Just In: ( NASDAQ: #CNSP ) CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

NEWS: ( NASDAQ: #CNSP ) JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live

CNS Pharmaceuticals Announces Reverse Stock Split CNS Pharmaceuticals (NASDAQ:CNSP) has announced a 1-for-12 reverse stock split of its common stock, effective July 22, 2025. The biopharmaceutical company's stock will continue trading on the Nasdaq Capital Market under the same symbol "CNSP" but with a new CUSIP number: 18978H508.Under this reverse split, every 12 shares will be automatically combined into one share, with proportional adjustments made to outstanding warrants and equity-based awards. The company's authorized shares will be reduced to 25 million, while maintaining a par value of $0.001 per share. Stockholders entitled to fractional shares will receive cash payments instead.

#CNSP CNS Pharmaceuticals Announces Reverse Stock Split

www.stocktitan.net/news/CNSP/cns-pharmaceut...

CNS Pharma CEO Shares Exclusive Insights on Novel Brain Cancer Treatment TPI 287 at Healthcare Leaders Meeting CEO John Climaco discusses breakthrough brain cancer drug TPI 287 and shares key insights from Longwood Healthcare Leaders meeting. Get exclusive updates.

#CNSP CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

www.stocktitan.net/news/CNSP/cns-pharmaceut...

Leading Neuro-Oncologist Reveals Breakthrough Potential of New Glioblastoma Drug TPI 287 Top brain tumor expert Dr. Dunbar discusses revolutionary GBM treatment approach and future applications for metastatic tumors. Watch exclusive insights now.

#CNSP CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

www.stocktitan.net/news/CNSP/cns-pharmaceut...

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update CNS Pharmaceuticals (NASDAQ:CNSP) reported its Q1 2025 financial results and provided updates on its lead program TPI 287. The company reported a net loss of $4.3 million, up from $3.5 million in Q1 2024, with R&D expenses increasing to $3.2 million. CNS ended Q1 with $13.1 million in cash and subsequently raised an additional $5 million through a public offering in May 2025, extending their cash runway into H2 2026. The company's lead drug candidate, TPI 287, an abeotaxane for treating glioblastoma multiforme (GBM), showed promising Phase 1 results with 3 Complete Responses and 9 Partial Responses out of 23 evaluable patients when combined with bevacizumab. CNS plans to commence a Phase 2 study around year-end 2025 and will engage with FDA for study design feedback. The company successfully transferred Orphan Drug Designations from Cortice Biosciences for TPI 287 in treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.

#CNSP CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CNSP/cns-pharmaceut...

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules CNS Pharmaceuticals (NASDAQ:CNSP) has announced the pricing of a $5 million public offering with a single healthcare-focused institutional investor. The offering includes 3,952,570 shares of common stock priced at $1.265 per share. Additionally, the company will issue Series F Warrants to purchase up to 3,952,570 shares with an exercise price of $1.14 per share, exercisable immediately and expiring in five years.The offering is expected to close around May 14, 2025. A.G.P./Alliance Global Partners is serving as the sole placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to an effective registration statement on Form S-1.

#CNSP CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/CNSP/cns-pharmaceut...

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 CNS Pharmaceuticals (NASDAQ:CNSP) has successfully acquired Orphan Drug Designation for TPI 287, a novel abeotaxane drug, from Cortice Biosciences. The FDA previously granted these designations for treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.TPI 287 works similarly to other taxanes by stabilizing microtubules and inhibiting cell division. Unlike most taxanes, clinical data suggests it can cross the blood-brain barrier. In a Phase 1 trial combining TPI 287 with bevacizumab for glioblastoma treatment, 3 Complete Responses and 9 Partial Responses were observed among 23 evaluable patients.The company plans to begin Phase 2 study enrollment by year-end 2025. The Orphan Drug Designation provides benefits including tax credits, FDA fee exemptions, and potential 7-year market exclusivity post-approval.

#CNSP CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

www.stocktitan.net/news/CNSP/cns-pharmaceut...

CNS Pharma's Strategic Shift: New Cancer Drug Focus as Losses Shrink 21% Despite Berubicin setback, CNS Pharma reduces losses by $4M and advances TPI 287 for glioblastoma treatment. Cash runway extended to 2026. Full analysis inside.

#CNSP CNS Pharmaceuticals Reports Full Year 2024 Financial Results

www.stocktitan.net/news/CNSP/cns-pharmaceut...

#Niger
#CNSP leader and Abdourahamane Tchiani, with the announcement of the New Refoundation Charter, was sworn in as General of the Army and President of the Republic. According to the refoundation roadmap outlined in the charter, depending on the security situation Tchiani will remain in president

Breaking News: ( NASDAQ: #CNSP ) BioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial

New Brain Cancer Drug Matches Standard Treatment with Better Safety Profile: Trial Results Novel anthracycline shows comparable efficacy to standard GBM treatment with superior safety profile and zero cardiotoxicity. Full analysis and implications inside.

#CNSP CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

www.stocktitan.net/news/CNSP/cns-pharmaceut...